Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes
Information source: University of British Columbia
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes
Intervention: glyburide (Drug); GlucoNorm (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of British Columbia Official(s) and/or principal investigator(s): Graydon Meneilly, MD, Principal Investigator, Affiliation: University of British Columbia
Summary
The results from the DECODE Study have shown that postprandial (1 - 2 hours after a meal)
hyperglycemia (elevated blood sugar) is more common in elderly people with diabetes than
younger people with diabetes and is the best predictor of the development of complications.
The DECODE Study involved 6941 people who already had diabetes and 702 who did not have
diabetes. Diabetes is diagnosed when the blood sugar 1st thing in the morning is over 7. 0
mmol/L. The DECODE Study showed that people at risk for diabetes can have a normal blood
sugar 1st thing in the morning but have a high blood sugar 2 hours after a meal and that
these people are at risk for developing heart disease and other complications of diabetes.
These people would not be identified as at risk if only a fasting blood sugar is done.
Studies in younger people with diabetes have shown that after a meal, insulin levels are
more like a person without diabetes and glucose (blood sugar) levels are lower with
GlucoNorm than with Glyburide. There is no data available that demonstrates this in elderly
people with type 2 diabetes.
You have been invited to participate in this study because you have type 2 diabetes
controlled by diet and/or exercise or metformin only and are over 65 years of age.
The purpose of this study is to determine whether GlucoNorm has a greater effect than
Glyburide on insulin levels and glucose (blood sugar) levels after a meal in elderly people
with type 2 diabetes who control their diabetes with diet and exercise.
Clinical Details
Official title: Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The objective of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and postprandial glucose levels in elderly people with type 2 diabetes who are diet controlled.
Detailed description:
The results from the DECODE Study have shown that postprandial hyperglycemia is more common
in elderly people with diabetes than younger people and is the best predictor of mortality
and morbidity. Studies in younger people with diabetes have shown that in response to a
meal, insulin profiles are more physiologic and glucose levels are lower with GlucoNorm than
with Glyburide. There is no data available that demonstrates this in elderly people with
type 2 diabetes.
This is a randomized, open-label, cross-over study. Subjects will undergo 2 Standard Meal
Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg
during the 1st Standard Meal Test and Glyburide 2. 5 mg during the 2nd Standard Meal Test.
Group 2 will receive Glyburide 2. 5 mg during the 1st Standard Meal Test and GlucoNorm 1mg
during the 2nd Standard Meal Test.
Eligibility
Minimum age: 65 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Type 2 diabetes > 3 months duration
- Male or female
- Over 65 years of age
- Diet controlled only
- HgbA1C < 8. 5%
Exclusion Criteria:
- Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring
treatment with these during the study.
- Anemia - hgb below 130 g/L (males) and below 120 g/L (females).
- Taking medications that known to interfere with glucose metabolism eg systemic
corticosteriods, non-selective beta blockers.
- Known or suspected allergy to glyburide, sulfa drugs or GlucoNorm impaired liver
function, as shown by but not limited to AST and/or ALT > 2x the upper limit of
normal.
- Impaired renal function, as shown by but not limited to serum creatinine > 133 µmol/L
(males) or 124 µmol/L (females).
- Participated in another clinical trial within the past 30 days.
Locations and Contacts
University of British Columbia, Vancouver, British Columbia, Canada
Additional Information
Starting date: November 2003
Last updated: February 17, 2014
|